Comparison of the effect of vitamin B6 and propranolol on Prevention of relapse of migraine headaches in children aged 7-17 years old referring to the pediatric clinic of Amirkabir Arak Hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191104045328N2

Enrollment

Registered

2020-01-25

Start date

2019-12-06

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migrain. Migraine

Interventions

Intervention 1: 31 patients given oral propranolol 10 mg once daily.The duration of the drug is three months. Intervention 2: Intervention group: 31 patients given oral vitamin B6 40 mg once daily .T

Eligibility

Sex/Gender

All

Age

7 Years to 17 Years

Inclusion criteria

Inclusion criteria: Children with migraine headaches at the age of 17-17 years who are allowed to study by their parents.

Exclusion criteria

Exclusion criteria: Propranolol contraindications, such as difficulty breathing, or wheezing, palms and feet cold, heart rate below 60 per minute, asthma or emphyzema, congestive heart failure, diabetes, hyperthyroidism, depression Kidney or liver failure Allergy to Vitamin B 6

Design outcomes

Primary

Measure	Time frame
Duration of Migraine Headache Attacks. Timepoint: Measured weekly by the patient himself at baseline and three months after taking the medication. Method of measurement: the watch.;The number of migraine headaches a week. Timepoint: Measured weekly by the patient himself at baseline and three months after taking the medication. Method of measurement: numbers.;The severity of headache disability. Timepoint: Measured weekly by the patient himself at baseline and three months after taking the medication. Method of measurement: with Pediatric Migraine Disability Assessment Score questionnaire.	—

Measure

Time frame

Duration of Migraine Headache Attacks. Timepoint: Measured weekly by the patient himself at baseline and three months after taking the medication. Method of measurement: the watch.;The number of migraine headaches a week. Timepoint: Measured weekly by the patient himself at baseline and three months after taking the medication. Method of measurement: numbers.;The severity of headache disability. Timepoint: Measured weekly by the patient himself at baseline and three months after taking the medication. Method of measurement: with Pediatric Migraine Disability Assessment Score questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ali Motafakker Azad

Arak University of Medical Sciences

ali_m_azad@yahoo.com+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026